FR3129833B1 - Nanoparticules pour la liberation d’acides nucleiques - Google Patents

Nanoparticules pour la liberation d’acides nucleiques Download PDF

Info

Publication number
FR3129833B1
FR3129833B1 FR2112931A FR2112931A FR3129833B1 FR 3129833 B1 FR3129833 B1 FR 3129833B1 FR 2112931 A FR2112931 A FR 2112931A FR 2112931 A FR2112931 A FR 2112931A FR 3129833 B1 FR3129833 B1 FR 3129833B1
Authority
FR
France
Prior art keywords
release
nucleic acids
nanoparticles
lipid
cationic lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2112931A
Other languages
English (en)
Other versions
FR3129833A1 (fr
Inventor
Giovanna Lollo
Valentina Andretto
David Kryza
Mouazen Eyad Al
Mathieu Repellin
Stéphanie Briancon
Laurent Schaeffer
Arnaud Jacquier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Hospices Civils de Lyon HCL
Universite Claude Bernard Lyon 1
Degli Studi Di Verona, University of
Universita degli Studi di Verona
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Hospices Civils de Lyon HCL
Universite Claude Bernard Lyon 1
Degli Studi Di Verona, University of
Universita degli Studi di Verona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR2112931A priority Critical patent/FR3129833B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS, Institut National de la Sante et de la Recherche Medicale INSERM, Hospices Civils de Lyon HCL, Universite Claude Bernard Lyon 1, Degli Studi Di Verona, University of, Universita degli Studi di Verona filed Critical Centre National de la Recherche Scientifique CNRS
Priority to PCT/EP2022/084174 priority patent/WO2023099722A1/fr
Priority to CA3239570A priority patent/CA3239570A1/fr
Priority to AU2022402342A priority patent/AU2022402342A1/en
Priority to US18/715,327 priority patent/US20250041221A1/en
Priority to CN202280080014.1A priority patent/CN118647361A/zh
Priority to JP2024532705A priority patent/JP2024544659A/ja
Priority to EP22830156.0A priority patent/EP4440545A1/fr
Publication of FR3129833A1 publication Critical patent/FR3129833A1/fr
Application granted granted Critical
Publication of FR3129833B1 publication Critical patent/FR3129833B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L’invention a trait à une nanoparticule comprenant un lipide cationique, un lipide neutre, et un lipide sensible au pH, différent dudit lipide cationique, utile comme vecteur pour le transport et la libération d’acides nucléiques à l’intérieur de cellules.
FR2112931A 2021-12-03 2021-12-03 Nanoparticules pour la liberation d’acides nucleiques Active FR3129833B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR2112931A FR3129833B1 (fr) 2021-12-03 2021-12-03 Nanoparticules pour la liberation d’acides nucleiques
CA3239570A CA3239570A1 (fr) 2021-12-03 2022-12-02 Nanoparticules pour la liberation d'acides nucleiques
AU2022402342A AU2022402342A1 (en) 2021-12-03 2022-12-02 Nanoparticles for release of nucleic acids
US18/715,327 US20250041221A1 (en) 2021-12-03 2022-12-02 Nanoparticles for release of nucleic acids
PCT/EP2022/084174 WO2023099722A1 (fr) 2021-12-03 2022-12-02 Nanoparticules pour la liberation d'acides nucleiques
CN202280080014.1A CN118647361A (zh) 2021-12-03 2022-12-02 用于释放核酸的纳米粒子
JP2024532705A JP2024544659A (ja) 2021-12-03 2022-12-02 核酸放出のためのナノ粒子
EP22830156.0A EP4440545A1 (fr) 2021-12-03 2022-12-02 Nanoparticules pour la liberation d'acides nucleiques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2112931A FR3129833B1 (fr) 2021-12-03 2021-12-03 Nanoparticules pour la liberation d’acides nucleiques
FR2112931 2021-12-03

Publications (2)

Publication Number Publication Date
FR3129833A1 FR3129833A1 (fr) 2023-06-09
FR3129833B1 true FR3129833B1 (fr) 2024-09-06

Family

ID=80225747

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2112931A Active FR3129833B1 (fr) 2021-12-03 2021-12-03 Nanoparticules pour la liberation d’acides nucleiques

Country Status (8)

Country Link
US (1) US20250041221A1 (fr)
EP (1) EP4440545A1 (fr)
JP (1) JP2024544659A (fr)
CN (1) CN118647361A (fr)
AU (1) AU2022402342A1 (fr)
CA (1) CA3239570A1 (fr)
FR (1) FR3129833B1 (fr)
WO (1) WO2023099722A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025151073A1 (fr) * 2024-01-10 2025-07-17 Agency For Science, Technology And Research Composition et nanoparticule appropriées pour être utilisées dans l'administration d'un agent thérapeutique
WO2025210592A1 (fr) * 2024-04-05 2025-10-09 Sanofi Pasteur Inc. Dosages de contrôle de qualité de lnp-arnm de cellules musculaires

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2941152B1 (fr) 2009-01-20 2013-10-18 Centre Nat Rech Scient Vecteurs comprenant une macromolecule anionique et un lipide cationique pour l'administration de petits acides nucleiques.
WO2013143555A1 (fr) 2012-03-26 2013-10-03 Biontech Ag Formulation d'arn pour immunothérapie
EP3315125A1 (fr) 2016-10-31 2018-05-02 Silence Therapeutics (London) Ltd Formulation de nanoparticules lipidiques
EP3906039A4 (fr) 2019-01-04 2023-01-18 Oncorus, Inc. Polynucléotides d'arn encapsulés et procédés d'utilisation
US20220313813A1 (en) * 2019-06-18 2022-10-06 Curevac Ag Rotavirus mrna vaccine
KR20220121246A (ko) 2019-12-20 2022-08-31 큐어백 아게 핵산 전달용 신규한 지질 나노입자

Also Published As

Publication number Publication date
JP2024544659A (ja) 2024-12-03
EP4440545A1 (fr) 2024-10-09
CA3239570A1 (fr) 2023-06-08
AU2022402342A1 (en) 2024-07-18
CN118647361A (zh) 2024-09-13
FR3129833A1 (fr) 2023-06-09
WO2023099722A1 (fr) 2023-06-08
US20250041221A1 (en) 2025-02-06

Similar Documents

Publication Publication Date Title
FR3129833B1 (fr) Nanoparticules pour la liberation d’acides nucleiques
Cserép et al. Bioorthogonal fluorescent labels: a review on combined forces
Wu et al. Programmable biopolymers for advancing biomedical applications of fluorescent nanodiamonds
Ploetz et al. Metal–organic framework nanoparticles induce pyroptosis in cells controlled by the extracellular pH
Klymchenko et al. Dye‐loaded nanoemulsions: biomimetic fluorescent nanocarriers for bioimaging and nanomedicine
Galiana et al. Preclinical antitumor efficacy of senescence-inducing chemotherapy combined with a nanoSenolytic
Liu et al. Biosafety evaluations of well-dispersed mesoporous silica nanoparticles: towards in vivo-relevant conditions
Butler et al. Protocells: modular mesoporous silica nanoparticle‐supported lipid bilayers for drug delivery
Perry et al. Mediating passive tumor accumulation through particle size, tumor type, and location
Shahabi et al. Modulation of silica nanoparticle uptake into human osteoblast cells by variation of the ratio of amino and sulfonate surface groups: effects of serum
Chakraborty et al. Design and synthesis of triphenylphosphonium functionalized nanoparticle probe for mitochondria targeting and imaging
Huang et al. PSMA-targeted stably linked “dendrimer-glutamate urea-methotrexate” as a prostate cancer therapeutic
Fahmy et al. Myoferlin plays a key role in VEGFA secretion and impacts tumor‐associated angiogenesis in human pancreas cancer
Yao et al. Near-infrared fluorogenic probes with polarity-sensitive emission for in vivo imaging of an ovarian cancer biomarker
Huang et al. Cationic conjugated polymer/fluoresceinamine-hyaluronan complex for sensitive fluorescence detection of CD44 and tumor-targeted cell imaging
MX2010001757A (es) Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo.
Klapper et al. Low affinity binding of plasma proteins to lipid-coated quantum dots as observed by in situ fluorescence correlation spectroscopy
Kirui et al. PAA‐derived gold nanorods for cellular targeting and photothermal therapy
FR2998899B1 (fr) Methode de criblage a haut-debit pour l'identification de biomarqueurs, cibles therapeutiques ou d'agents therapeutiques
Welsher et al. Discovery of protein-and DNA-imperceptible nanoparticle hard coating using gel-based reaction tuning
Vecchione et al. Ultrastable liquid–liquid interface as viable route for controlled deposition of biodegradable polymer nanocapsules
Sardan et al. Noncovalent functionalization of mesoporous silica nanoparticles with amphiphilic peptides
Shahabi et al. Amino acid-catalyzed seed regrowth synthesis of photostable high fluorescent silica nanoparticles with tunable sizes for intracellular studies
Tong et al. Mitochondria‐targeted bovine serum albumin@ copper sulfide nanocomposites conjugated with rhodamine‐110 dye for an enhanced efficacy of cancer photothermal therapy
US20220273823A1 (en) Theranostic conjugates

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20230609

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5